Otezla only shows moderate efficacy by week 16. about 28% show improvement. but Celgene will get 2 billion bucks for this next year.

Vitae has a psoriasis drug that moderates Interleukin-17. They did a deal for 640 million bucks. Dr. Reddy's did deal for Xenocort for half a billion. Another big deal for a monoclonal antibody. (editorial comment: monoclonal antibodies often have bad side effects.)

Dr. B's point: there's a big market out there with lots of deals.